Business Context and Reporting Period
Allarity Therapeutics, Inc. (Nasdaq: ALLR), an emerging growth company, filed this Form 8-K on September 15, 2023, reporting events occurring on September 14 and 15, 2023. The filing details a material definitive agreement involving the inducement of warrant holders to exercise existing warrants and the issuance of new warrants.
Key Financial Metrics and Transaction Details
- Transaction Type: Inducement agreement to reduce warrant exercise prices and issue new warrants.
- Reduced Exercise Price: $1.00 per share (matching the closing stock price on September 14, 2023).
- Existing Warrant Exercise: Two holders agreed to purchase up to 2,538,889 shares of common stock.
- Expected Gross Proceeds: Approximately $2,538,889 from the exercise of existing warrants (before fees).
- New Warrant Issuance: Issuance of new warrants to purchase up to 5,077,778 shares (2x the shares exercised under existing warrants) at the $1.00 exercise price.
- Transaction Costs: 7.0% financial advisory fee to A.G.P./Alliance Global Partners plus up to $50,000 in reimbursable legal expenses.
- Use of Proceeds: General corporate purposes.
Material Changes and Agreements
The filing reports a significant change in the capital structure terms for specific warrant holders. The Company entered into an Inducement Letter with two holders of April 2023 and July 2023 warrants. Key changes include:
- Price Reduction: The exercise price for the Existing Warrants was reduced to $1.00 for all holders, but the inducement (new warrants) applies only to the two participating holders.
- Waiver Agreement: A limited waiver was obtained from 3i, LP to allow the filing of a resale registration statement. In consideration, the Company agreed to amend the conversion price of its Series A Convertible Preferred Stock to equal the $1.00 Reduced Warrant Exercise Price.
- Liquidated Damages: The Company agreed to pay 1.5% of the aggregate exercise price of New Warrants per 30-day period if it fails to provide required public information or obtain necessary stockholder approval, preventing holders from selling shares.
Outlook, Risks, and Contingencies
- Closing Date: Expected on September 18, 2023, subject to customary closing conditions.
- Registration Requirements: The Company must file a Form S-3 (or appropriate form) for the resale of New Warrant Shares by October 15, 2023, and keep it effective until all New Warrants are exercised or expire.
- Liquidity Risk: There is no established trading market for the New Warrants, and the Company does not expect one to develop, resulting in extremely limited liquidity for these instruments.
- Exercisability: New Warrants are immediately exercisable after the Stockholder Approval Date (or six months post-issuance if approval is not required) and expire 5 years and 6 months after that date.
- Ownership Limits: Holders are restricted from exercising if it would result in ownership exceeding 4.99% (or 9.99% with notice) of outstanding common stock.
Investor Verification Checklist
- Verify the actual closing of the transaction on or around September 18, 2023.
- Confirm the filing and effectiveness of the Resale Registration Statement (Form S-3) by October 15, 2023.
- Monitor the amendment of the Series A Convertible Preferred Stock conversion price to $1.00.
- Assess the dilution impact of the 5,077,778 new warrant shares and the 2,538,889 shares from existing warrant exercises.
- Review the Company's cash position to ensure it can cover the 7% advisory fee and legal expenses.